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TheCREB-regulated transcriptioncoactivatorCRTC2
stimulates CREB target gene expression and has
a well-established role in modulating glucose and
lipid metabolism. Here, we find, unexpectedly, that
loss of CRTC2, as well as CREB1 and its coactivator
CREB-binding protein (CBP), results in a defi-
ciency in DNAmismatch repair (MMR) and a resultant
increasedmutation frequency. We show that CRTC2,
CREB1, and CBP are transcriptional activators
of well-established MMR genes, including EXO1,
MSH6, PMS1, and POLD2. Mining of expression
profiling databases and analysis of patient samples
reveal that CRTC2 and its target MMR genes
are downregulated in specific T cell lymphoma sub-
types, which are microsatellite unstable. The levels
of acetylated histone H3 on the CRTC2 promoter are
significantly reduced in lymphoma in comparison to
normal tissue, explaining the decreased CRTC2
expression. Our results establish a role for CRTC2
asa lymphoma tumorsuppressorgene thatpreserves
genome integrity by stimulating transcription of MMR
genes.
INTRODUCTION
In response to a variety of extracellular signals, the transcription
factor CREB regulates diverse cellular responses by modulating
the expression of genes containing a cAMP-response element
(CRE) (Shaywitz and Greenberg, 1999). CREB works in concert
with its coactivator, CREB-binding protein (CBP; also called
CREBBP) and, depending on cellular context, with a family of
coactivators called CREB-regulated transcription coactivators
(CRTCs) (Altarejos and Montminy, 2011). Of the CRTC family
members, CRTC2 is thought to be the major mediator of CREB
target gene expression (Conkright et al., 2003).
DNA mismatch repair (MMR) is an evolutionarily conserved
process that is responsible for recognizing and repairing sin-
gle-base mismatches and small insertion/deletion loops that1350 Cell Reports 11, 1350–1357, June 9, 2015 ª2015 The Authorsare formed during DNA replication (Jiricny, 2006). Cells deficient
for MMR have higher mutation rates relative to normal cells.
Consequently, genetic and epigenetic modifications that impair
the expression of genes required for MMR, especially MSH2,
MSH6, and MLH1, cause susceptibility to certain types of
cancer and have a so-called mutator phenotype that can be
detected in eukaryotic cells as microsatellite instability (MSI)
(Kolodner, 1996; Modrich and Lahue, 1996). Mutations in
MMR genes are frequently found in MSI-positive hereditary
nonpolyposis colorectal cancer (Peltoma¨ki, 2003). A significant
fraction of non-hereditary colorectal cancers are also MSI pos-
itive but do not carry a detectable mutation or epigenetic modi-
fication of known MMR genes (Peltoma¨ki, 2003), suggesting
that in these cases other molecular aberrations are the basis
of MSI. Here we report that CRTC2 plays an important role in
maintaining genome integrity and functions by promoting tran-
scription of MMR genes.
RESULTS AND DISCUSSION
Loss of CRTC2 Results in Defective MMR
Several previous findings prompted us to analyze the possible
role of CRTC2 as a tumor suppressor that functions in MMR.
First, mining of the COSMIC (Catalogue of Somatic Mutations
in Cancer) database (Forbes et al., 2011) revealed that CRTC2
is recurrently mutated in several cancer types (Table S1).
Second, a search of the Oncomine cancer profiling database
(Rhodes et al., 2007) revealed that CRTC2 is downregulated
in multiple cancers (Figure S1). Third, analysis of a previ-
ous genome-wide occupancy study (Zhang et al., 2005)
revealed that CREB1 was bound to several genes with well-
established roles in MMR (see below), raising the possibility
that CRTC2 may also bind to and regulate MMR gene
expression.
To investigate the possible role of CRTC2 in MMR, we con-
structed CRTC2 knockout (KO) cell lines using a CRISPR/Cas9
genome editing strategy. The experiments were performed in
HeLa cells, a commonly used MMR proficient, microsatellite
stable cell line. Immunoblot analysis shows that CRTC2 was
undetectable in two independently derived CRTC2 KO HeLa
clones (Figure 1A), and sequencing confirmed that both alleles
in each cell line were disrupted (Figure S2A).
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Figure 1. Loss of CRTC2, CREB1, or CBP
Results in Defective MMR and a Mutator
Phenotype
(A) Immunoblot analysis monitoring CRTC2 levels
in control or CRTC2 KO HeLa cells. a-tubulin
(TUBA) was monitored as a loading control.
(B and C) MMR activity assay (B) and spontaneous
mutation frequency (C) in control or CRTC2 KO
HeLa cells.
(D) MSI analysis. Control HeLa cells and CRTC2
KO HeLa subclones were analyzed for MSI at
BAT25, BAT26, D2A123, and D5S346. Red aster-
isks indicate new microsatellite species or micro-
satellite deletions.
(E and F) MMR activity assay (E) and spontaneous
mutation frequency (F) in HeLa cells expressing a
NS, CREB1, or CBP shRNA. For all graphs, error
bars indicate SD. **p < 0.01.
(G) MSI analysis in HeLa cells expressing a NS,
CREB1, or CBP shRNA.
See also Figures S1 and S2.To determine whether CRTC2 KO HeLa cells had reduced
MMR activity, we performed an in vivo MMR activity assay that
monitored repair of a single-base mismatch in an enhanced
GFP (EGFP) reporter gene (Zhou et al., 2009). Cells that are pro-
ficient for MMR correctly repair the mismatch and therefore ex-
press EGFP. The results show that CRTC2 KO HeLa cells had
greatly reduced MMR activity compared with control HeLa cells
(Figures 1B and S2B). Ectopic expression of CRTC2 in CRTC2
KO HeLa cells largely restored MMR activity (Figures S2C and
S2D), ruling out the possibility that the reduced MMR activity
we observed was due to an off-target effect.
To determine whether MMR-defective CRTC2 KO HeLa
cells had a mutator phenotype, we measured the spontaneous
mutation frequency of the hypoxanthine guanine phosphoribo-
syltransferase (HPRT) gene. The results show that the sponta-
neous mutation frequency in CRTC2 KO HeLa cells was
25-fold higher than in control HeLa cells (Figure 1C). We
also tested whether CRTC2 KO HeLa cells had MSI by
analyzing four loci, BAT25, BAT26, D2S123, and D5S346,
which are commonly used to diagnose MSI (Boland et al.,
1998; Parsons et al., 1993). As expected, we observed no evi-
dence of MSI in control HeLa cells, whereas all four CRTC2
KO1 HeLa subclones and two of the four CRTC2 KO2 HeLa
subclones examined showed new microsatellite species, indic-
ative of MSI (Figure 1D).Cell Reports 11, 1350–13Loss of CREB1 or CBP Leads to
Decreased MMR and a Mutator
Phenotype
To determine whether loss of CREB1 or
CBP produced a phenotype similar to
that of CRTC2 KO, we performed an
in vivo MMR activity assay in HeLa cells
expressing a control non-silencing (NS)
short hairpin RNA (shRNA) or one of
two unrelated CREB1 or CBP shRNAs.
MMR activity was significantly reduced
in CREB1 knockdown (KD) and CBP KDcells compared with control NS HeLa cells (Figures 1E and
S2E–S2G). Likewise, CREB1 or CBP KD cells had a higher spon-
taneous mutation frequency than control NS cells (Figure 1F).
Finally, 5 of 14 CREB1 or CBP KD cell lines produced newmicro-
satellite species or microsatellite deletions, indicative of MSI
(Figure 1G).
CRTC2, CREB1, and CBP Bind to the Promoters and
Stimulate Transcription of Select MMR Genes
Next, we sought to investigate the mechanism by which
CRTC2, CREB1, and CBP promote MMR. We mined a pub-
lished CREB1 genome-wide occupancy study (Zhang et al.,
2005) and identified four MMR genes that are bound by
CREB1: EXO1, MSH6, PMS1, and POLD2 (Jiricny, 2006). Motif
search analysis confirmed the presence of a CRE in the pro-
moters of these MMR genes (Figure S3A). To confirm and
extend the results of the genome-wide occupancy study, we
performed chromatin immunoprecipitation (ChIP) assays. In
HeLa cells, CRTC2, CREB1, and CBP were directly bound to
the promoters of EXO1, MSH6, PMS1, and POLD2 at the pre-
dicted CRE sites (Figure 2A), indicating that these genes
are direct targets of CRTC2, CREB1, and CBP. Therefore,
we refer to these four MMR genes as ‘‘target MMR genes’’
below. As expected, binding of CRTC2 and CBP was substan-
tially reduced in CREB1 KD cells (Figures 2B and S3B).57, June 9, 2015 ª2015 The Authors 1351
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Figure 2. CRTC2, CREB1, and CBP Bind to
the Promoters and Stimulate Transcription
of MMR Genes
(A) ChIP analysis monitoring occupancy of CRTC2,
CREB1, and CBP on the promoters of EXO1,
MSH6, PMS1, and POLD2 or an irrelevant negative
control (NC) DNA region.
(B) ChIP analysismonitoring occupancy of CRTC2,
CREB1, and CBP on the promoters of EXO1,
MSH6, PMS1, and POLD2 in HeLa cells express-
ing a NS or CREB1 shRNA.
(C) ChIP analysismonitoring occupancy of CRTC2,
CREB1, and CBP on the promoters of EXO1,
MSH6, PMS1, and POLD2 in control or CRTC2 KO
HeLa cells.
(D and E) qRT-PCR monitoring expression of
EXO1, MSH6, PMS1, and POLD2 in control or
CRTC2 KO HeLa cells (D) or in HeLa cells
expressing a NS, CREB1, or CBP shRNA (E). For
all graphs, error bars indicate SD. *p < 0.05,
**p < 0.01.
See also Figure S3.Notably, in CRTC2 KO cells, CBP recruitment was substan-
tially decreased and CREB1 binding was also diminished
(Figure 2C).
We next investigated whether CRTC2, CREB1, and CBP
are transcriptional activators of the target MMR genes. The
quantitative real-time RT-PCR (qRT-PCR) analysis shows
that CRISPR/Cas9-mediated KO of CRTC2 substantially
decreased target MMR gene expression (Figure 2D), which
was largely restored by ectopic expression of CRTC2 (Fig-
ure S3C). Immunoblot analysis confirmed reduced expression
of EXO1, MSH6, PMS1, and POLD2 at the protein level in
CRTC2 KO cells (Figure S3D). Finally, shRNA-mediated KD
of CRTC2 (Figures S3E and S3F) or CREB1 or CBP (Figures
2E and S3G) also substantially decreased target MMR gene
expression.
The CREB-CRTC2 Pathway Is Stimulated by DNA
Damage, Resulting in Upregulation of Target MMR
Genes
Next, we sought to investigate whether CRTC2, CREB1, and
CBP could promote expression of target MMR genes under1352 Cell Reports 11, 1350–1357, June 9, 2015 ª2015 The Authorsconditions of DNA damage. In most cell
types, CRTC2 and its family members
are phosphorylated by LKB1-AMP-acti-
vated protein kinase (AMPK) signaling
(Shackelford and Shaw, 2009) and are
sequestered in the cytoplasm until
cAMP triggers dephosphorylation and
nuclear entry (Bittinger et al., 2004;
Screaton et al., 2004). However, HeLa
cells lack functional LKB1 (Katoh et al.,
2006) and, as a result, have a constitu-
tively active CREB-CRTC2 pathway that
makes them unsuitable for studying
possible regulation of the pathway by
DNA damage. Therefore, we insteadused as a model system the LKB1-positive human embryonic
kidney cell line, HEK293T. DNA damage by UV irradiation re-
sults in phosphorylation of CREB1 at S133 and increased
CREB1 transcriptional activity (Iordanov et al., 1997). We there-
fore reasoned that induction of DNA damage in HEK293T cells
would activate the CREB-CRTC2-mediated pathway of target
MMR gene activation.
As a positive control in these experiments, we used forskolin,
an adenylyl cyclase agonist that increases intracellular levels
of cAMP, resulting in both phosphorylation of CREB1 at S133
and dephosphorylation of CRTC2 (Screaton et al., 2004). Like
forskolin, UV irradiation of HEK293T cells promoted CRTC2
dephosphorylation (Figure S3H), and resulted in increased bind-
ing of CREB1, CRTC2, and CBP to target MMR gene promoters
(Figure S3I) as well as increased target MMR gene expression
(Figure S3J). Consistent with these results, ectopic expression
of a constitutively active CRTC2 phosphorylation defective
mutant (CRTC2-S171A) in HEK293T cells also resulted in
increased target MMRgene expression (Figure S3K). In contrast,
in UV-treated HEK293T cells, ectopic expression of a CREB1
phosphorylation defective mutant (CREB1-S133A) (Figure S3L)
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(A) Soft agar assay. NIH 3T3 cells stably express-
ing a NS, Crtc2, Exo1, or Msh6 shRNA were
analyzed for colony formation, which was
normalized to that obtained in cells expressing NS
shRNA, which was set to 1.
(B) Representative examples of immunohisto-
chemistry for CRTC2 in normal (tonsil) and two
independent lymphoma tissue samples. Scale
bars represent 100 mM.
(C) MSI analysis at BAT25, BAT26, D2A123, and
D5S346 in normal and in lymphoma samples. Non-
adjacent lanes from the same gel were spliced
together as indicated by the dividing lines.
(D) qRT-PCR monitoring CRTC2 expression in
normal and lymphoma samples.
(E) qRT-PCR analysis monitoring expression of
EXO1, MSH6, PMS1, and POLD2 in normal and
lymphoma samples with loss of CRTC2 expres-
sion. For all graphs, error bars indicate SD. *p <
0.05, **p < 0.01.
(F) MSI analysis at BAT25, BAT26, D2A123, and
D5S346 in normal and lymphoma samples with
loss of CRTC2 expression.
See also Figure S4.did not stimulate target MMR gene expression (Figure S3M).
Collectively, these results show that following DNA damage,
CREB-CRTC2 pathway activity is increased through regulation
of both CREB1 and CRTC2, resulting in increased expression
of MMR target genes.
Decreased Expression of CRTC2 in Specific Lymphoma
Subtypes
SeveralMMRgenes, such asMSH2 andMLH1, are known tumor
suppressor genes (Li, 2008). Our finding that CRTC2 is required
for expression of MMR genes raised the possibility that CRTC2
may be a tumor suppressor gene. We therefore sought to deter-
mine whether loss of CRTC2would transform cells. For these ex-
periments we used LKB1-positive mouse NIH 3T3 fibroblasts,
which are immortalized but not transformed and can be rendered
tumorigenic by a wide range of oncogenic events (see, for
example, Di Fiore et al., 1987; Smith et al., 1990; Stacey and
Kung, 1984; Velu et al., 1987). As expected, in NIH 3T3 cells
expression of the four CRTC2 target MMR genes was greatly
reduced upon shRNA-mediated KD of Crtc2 (Figures S4A and
S4B). Most importantly, KD of Crtc2, or a target MMR gene
(Exo1 or Msh6; Figures S4C and S4D), promoted anchorage-in-
dependent growth of NIH 3T3 cells, as evidenced by increased
colony formation in a soft agar assay (Figures 3A and S4E).Cell Reports 11, 1350–13Mining of the Oncomine database re-
vealed that CRTC2 is downregulated
in multiple cancer types, with the most
significant downregulation occurring in
several subtypes of lymphoma such as
anaplastic large cell lymphoma (ALCL),
angioimmunoblastic T cell lymphoma
(ATCL), and peripheral T cell lymphomaunspecified (PTCL/U) (Piccaluga et al., 2007) (see Figure S1).
We therefore elected to focus on the role of CRTC2 as a tumor
suppressor in lymphoma.
To confirm that CRTC2 is downregulated in lymphoma,
we analyzed CRTC2 expression in formalin-fixed, paraffin-
embedded ALCL, ATCL, and PTCL/U lymphoma patient samples
by immunohistochemistry. CRTC2 stainingwas strong in lympho-
cytes from normal tonsils but was greatly reduced in 23 of 24
lymphomas analyzed (Figure 3B; Table S2). Notably, seven of
ten samples analyzed displayed new species of microsatellite or
microsatellite deletions (Figure 3C), confirming MSI and verifying
that lymphomas with decreased CRTC2 are deficient in MMR.
To extend our findings, we analyzed CRTC2 expression in
seven snap-frozen ALCL, ATCL, and PTCL/U lymphoma patient
samples, from which we could isolate mRNA. The qRT-PCR
results show that the levels of CRTC2mRNA in normal tonsil tis-
sues were roughly equivalent; however, they were significantly
reduced in four of seven human lymphoma samples analyzed
(Figure 3D; see also Table S2). qRT-PCR analysis in the four lym-
phoma samples with reduced CRCT2 expression confirmed that
expression of EXO1,MSH6, PMS1, and POLD2 was downregu-
lated (Figure 3E). Finally, three of four lymphomas with reduced
CRTC2 expression produced newmicrosatellite species, indica-
tive of MSI (Figure 3F).57, June 9, 2015 ª2015 The Authors 1353
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Figure 4. Reduced CRTC2 Expression in Lymphoma Cell Lines and Patient Samples due to Decreased Acetylation of Histone H3
(A) qRT-PCR analysis monitoring expression of CRTC2, EXO1, MSH6, PMS1, and POLD2 in Jurkat, Karpas 299, and SUDHL-1 cells.
(B) MSI analysis at BAT25, BAT26, D2A123, and D5S346 in Jurkat, Karpas 299, and SUDHL-1 cells.
(C) qRT-PCR analysis monitoring expression of CRTC2, EXO1, MSH6, PMS1, and POLD2 in Jurkat, Karpas 299 and SUDHL-1 cells treated with 5-aza, TSA,
or both.
(D) ChIP analysis monitoring histone H3 acetylation (acetyl-H3) levels on the CRTC2 promoter in Jurkat, Karpas 299, and SUDHL-1 cells.
(E) PAT-ChIP assay monitoring acetyl-H3 levels of the CRTC2 promoter in normal and lymphoma samples. For all graphs, error bars indicate SD. *p < 0.05,
**p < 0.01.
(F) Schematic model.Reduced CRTC2 Expression in Lymphoma Cell Lines
and Patient Samples due to Decreased Acetylation of
Histone H3
Tumor suppressor genes are frequently inactivated at the tran-
scriptional level due to epigenetic silencing resulting from DNA
hypermethylation or alterations in histone modifications such
as loss of histone H3 acetylation (Baylin and Jones, 2011). To
investigate whether CRTC2 was epigenetically silenced in lym-
phoma, we analyzed two previously described patient-derived
ALCL cell lines, Karpas 299 and SUDHL-1 (Quintanilla-Martinez
et al., 2006). We first confirmed that CRTC2 expression, as well1354 Cell Reports 11, 1350–1357, June 9, 2015 ª2015 The Authorsas that of EXO1,MSH6, PMS1, and POLD2, was reduced in the
two ALCL cell lines relative to Jurkat cells, a cell line derived from
a patient with T cell leukemia (Schneider et al., 1977) (Figure 4A).
As expected, we observed no evidence of MSI in Jurkat cells,
whereas all four Karpas 299 subclones and SUDHL-1 subclones
examined showed new microsatellite species or microsatellite
deletions, indicative of MSI (Figure 4B).
To determine the mechanism by which CRTC2 was silenced,
we treated Karpas 299 and SUDHL-1 cells with 5-azacytidine
(5-aza), a DNA methyltransferase inhibitor, trichostatin A (TSA),
a histone deactylase inhibitor, or both drugs and monitored
CRTC2 expression by qRT-PCR. Figure 4C shows that treatment
of Karpas 299 or SUDHL-1 cells with 5-aza had no effect on
CRTC2 expression, whereas treatment with TSA significantly
increased CRTC2 expression. In contrast, treatment of Jurkat
cells with either 5-aza or TSA had no effect on CRTC2 expres-
sion. Similar results were obtained for EXO1, MSH6, PMS1,
and POLD2.
To confirm these pharmacological results, we performed ChIP
analysis for acetylated histone H3. Figure 4D shows that the level
of H3 acetylation on the CRTC2 promoter was much higher in
Jurkat cells than in Karpas 299 or SUDHL-1 cells. Finally, to
determine the clinical relevance of these cell culture results, we
performed pathology-tissue (PAT)-ChIP (Fanelli et al., 2011) for
acetylated H3 in formalin-fixed, paraffin-embedded lymphoma
patient samples that showed reduced CRTC2 expression. Fig-
ure 4E shows that levels of acetylated H3 on the CRTC2 pro-
moter were significantly lower in lymphomas than in the control
normal tonsil tissue.
In this report, we describe an unanticipated role for the CREB
transcriptional activator CRTC2, as well as CREB1 and CBP, in
MMR, which is summarized in the model of Figure 4F. We find
that in certain subtypes of lymphoma, CRTC2 is epigenetically
silenced, resulting in downregulation of several well-known
MMR genes and MSI. We further show that KD of CREB1 or
CBP also leads to decreased MMR and MSI. Consistent with
our findings, previous studies have shown CBP is mutated in a
high percentage of MSI-positive colon cancer cell lines, and
loss of CBP correlates with inactivation of MMR (Ionov et al.,
2004). These previous findings, in conjunction with the results
of our study, suggest that in certain cancers alterations of tran-
scription coactivators CRTC2 and CBP lead to the decreased
expression of MMR genes and MSI. Our results help to explain
why genetic or epigenetic abnormities in MMR genes have not
been observed in some MSI-positive cancers (Peltoma¨ki, 2003).
EXPERIMENTAL PROCEDURES
Cell Lines and Culture
HeLa cells (American Type Culture Collection; ATCC) were cultured in DMEM.
Karpas 299 and SUDHL-1 cells (provided by Dr. Youli Zu, Houston Methodist
Hospital) and Jurkat cells (ATCC) were maintained in RPMI medium with 10%
fetal bovine serum (FBS). Jurkat, Karpas 299, and SUDHL-1 cells were treated
with10mM5-aza-20-deoxycytidine (50-aza; Sigma-Aldrich) for 3 days, 500nMtri-
chostatin A (TSA; Sigma-Aldrich) for 12 hr, or a combination of both (where TSA
treatment was administered for the last 12 hr of the 3-day 5-aza treatment).
CRISPR/Cas9-Mediated KO
Candidate target sequences for CRISPR were designed using CRISPR
Design Tool (http://tools.genome-engineering.org). The guide RNA to target
nucleotides 199–218 (ATGGGTATGGGGGTAACCGC) in the second exon of
CRTC2 was cloned into pX459 (Addgene) and transfected into HeLa cells.
Two days later, transfected cells were selected with 1.5 mg/ml puromycin for
more than 3 weeks to generate stable KO cell lines. Eight single colonies
were randomly picked, expanded, and confirmed for loss of CRTC2 expres-
sion by immunoblotting. Two of these clones were randomly selected to
confirm the CRTC2 mutations by sequencing and used in all subsequent
analyses.
shRNA-Mediated KD
Cells were stably transduced with shRNA viruses from Open Biosystems/
Thermo Scientific and selected with puromycin.CImmunoblot Analysis
Protein extracts were prepared by lysis in a buffer containing 50 mM Tris-HCl
(pH 7.4), 0.1% Triton X-100, 5 mM EDTA, 250 mM NaCl, 50 mM NaF, 0.1 mM
Na3VO4, and protease inhibitor (Roche). Blots were probed with the following
antibodies: anti-CRTC2 (Santa Cruz), anti-CREB1 (Cell Signaling), anti-
a-tubulin (Sigma-Aldrich), and anti-EXO1, anti-MSH6, anti-PMS1, and anti-
POLD2 (all from One World Lab).
Real-Time qRT-PCR
Total RNAwas isolated, and reverse transcriptionwas performed as described
previously (Gazin et al., 2007), followed by real-time qPCRwith PlatinumSYBR
green qPCR SuperMix-UDG with Rox (Invitrogen).
DNA MMR Assay
The in vivo DNA MMR assay was performed as previously described (Zhou
et al., 2009). Briefly, an EGFP heteroduplexed reporter plasmid containing
a mismatch loop was prepared using plasmids p111 and p189 (provided
by LuZhe Sun, University of Texas Health Science Center at San Antonio)
and cotransfected with pDsRed-N1 (Clontech) into cells. The percentage
of EGFP+ and Ds-Red+ cells was analyzed by fluorescence-activated cell
sorting (FACS) using a Becton Dickinson FACSCalibur flow cytometer. The
normalized ratio of EGFP+ cells was calculated as the percentage of
EGFP+, DsRed+ cells divided by the percentage of DsRed+ cells (i.e., the
sum of EGFP+, DsRed+ cells and EGFP, DsRed+ cells), which in control
cells was set to 1.
Spontaneous Mutation Frequency
The HPRT mutation assay was conducted as described previously (Kat et al.,
1993). The mutation frequency was determined by dividing the number of
6-thioguanine-resistant colonies by the total number of cells plated after being
corrected for colony-forming ability.
MSI Analysis
Genomic DNA was isolated from either single-cell colonies picked or isolated
in 96-well microtiter plates (for cell lines) or from patient samples. Microsatellite
markers BAT25, BAT26, D2S123, and D5S346 were analyzed (Parsons et al.,
1993) with improved primers as described (Umetani et al., 2000).
ChIP Assays
ChIP assays were performed as previously described (Raha et al., 2005)
using an anti-CRTC2 (Bethyl Laboratories), anti-CREB1 (Cell Signaling
Technology), anti-CBP (Bethyl Laboratories), or anti-histone H3 (acetyl
K9+K14+K18+K23+K27; Abcam, ab47915) antibody. ChIP products were
analyzed by qPCR. Samples were quantified as percentage of input and
then normalized to an irrelevant region in the genome (3.2 kb upstream
from the transcription start site of GCLC). Fold enrichment was calculated
by setting the IgG control immunoprecipitation (IP) sample to 1.
Lymphoma Sample Analysis
Formalin-fixed paraffin-embedded tissue sections of normal tonsil (n = 7)
and lymphoma (n = 24) and snap-frozen samples of normal tonsil (n = 4)
and lymphoma (n = 7) were obtained from the archived pathology files of
the Pathology Department at the University of Massachusetts Medical
School (UMMS), and the lymphoma diagnosis was made by a UMMS
pathologist (see Table S2). This study was approved by the institutional
review board at UMMS. Immunohistochemical analysis was carried out as
previously described (Wajapeyee et al., 2008), using a CRTC2 antibody
(1:150 dilution; Santa Cruz). For PAT-ChIP, sections were deparaffinized,
rehydrated, and processed as previously described (Fang et al.,
2014) using an anti-histone H3 (acetyl K9+K14+K18+K23+K27; Abcam,
ab47915) antibody.
Statistics
All quantitative data were collected from experiments performed in at least
triplicate and expressed as mean ± SD. Differences between groups were
assayed using two-tailed Student’s t test using Microsoft Excel. Significant
differences were considered when p% 0.05.ell Reports 11, 1350–1357, June 9, 2015 ª2015 The Authors 1355
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